Logo

Sol-Gel Technologies' Twyneo (tretinoin/benzoyl peroxide) Cream Receives the US FDA's Approval for the Treatment of Acne Vulgaris

Share this

Sol-Gel Technologies' Twyneo (tretinoin/benzoyl peroxide) Cream Receives the US FDA's Approval for the Treatment of Acne Vulgaris

Shots:

  • The approval is based on two P-III studies that evaluate Twyneo vs vehicle in adults & pediatric patients aged ≥9yrs. with acne vulgaris which demonstrated an efficacy & a favorable tolerability profile
  • Twyneo utilizes Sol-Gel’s microencapsulation technology to entraps tretinoin & benzoyl peroxide within silica-based microcapsules. Additionally- the company collaborated with Galderma to commercialize Twyneo in the US
  • Sol-Gel to receive a regulatory milestone in conjunction with FDA's approval & retains the option to regain US commercialization rights for five yrs. after the 1st commercialization in the US. Twyneo is patent protected until 2038

Ref: Sol-Gel | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions